department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

494 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT799 Endpoints603 BioPharma Dive231 onclive165 Fierce Biotech73 BioSpace69 raps29

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology

<![CDATA[Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma]]>
<![CDATA[Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.]]>
onclive · 2mo ago↗ source
<![CDATA[FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC]]>
<![CDATA[An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC]]>
onclive · 2mo ago↗ source
<![CDATA[Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer]]>
<![CDATA[]]>
onclive · 2mo ago↗ source

page 18 of 20

6

Infectious Disease4

<![CDATA[Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma]]>

<![CDATA[Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Sznol on Biomarkers of Response in Metastatic Melanoma]]>

<![CDATA[Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma. ]]>

onclive · 2mo ago↗ source

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

<figure><div><img src="https://imgproxy.divecdn.com/gRkyNZ1AbgGTL_5MqeKhbG0YuhnzTHcUYxQb5ULTKUc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA4MzAxNTQ0LmpwZ…

BioPharma Dive · 2mo ago↗ source

<![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>

<![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>

onclive · 2mo ago↗ source

Novo hikes guidance on Wegovy pill’s fast sales start

<p>In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pil…

BioPharma Dive · 2mo ago↗ source

Avalo shares spike on skin drug data; BioNTech to cut staff

<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…

BioPharma Dive · 2mo ago↗ source

<![CDATA[ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go]]>

<![CDATA[Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>

onclive · 2mo ago↗ source

<![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]>

<![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>

onclive · 2mo ago↗ source

<![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]>

<![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>

onclive · 2mo ago↗ source

<![CDATA[Disease Assessment and Mutational Testing in Progressive CLL]]>

<![CDATA[Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.]]>

onclive · 2mo ago↗ source

<![CDATA[Clinical Scenario Presentation and Treatment Approach for Progressive Disease]]>

<![CDATA[Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC]]>

<![CDATA[Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.]]>

onclive · 2mo ago↗ source

<![CDATA[Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026]]>

<![CDATA[SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.]]>

onclive · 2mo ago↗ source

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

<figure><div><img src="https://imgproxy.divecdn.com/aUhcesS0eCO3NThNNqPfIC_gM2-0lSalzL7WEg-RP7g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02ODA4MDQ3ODAuanBn.…

BioPharma Dive · 2mo ago↗ source

<![CDATA[Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC]]>

<![CDATA[Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer ]]>

<![CDATA[Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Pant on Managing Toxicities With Daraxonrasib in PDAC]]>

<![CDATA[Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.]]>

onclive · 2mo ago↗ source

<![CDATA[HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance]]>

<![CDATA[Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.]]>

onclive · 2mo ago↗ source

<![CDATA[Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress]]>

<![CDATA[Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.]]>

onclive · 2mo ago↗ source

Viridian data lift prospects for thyroid eye disease drug

<figure><div><img src="https://imgproxy.divecdn.com/egbyTu8esim-VjYj5FTvMQUlBrndW-s35OSn02s-EoY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzk4NTE5MTYzLmpwZ…

BioPharma Dive · 2mo ago↗ source

<![CDATA[The Type of Fat—Not the Amount—Fuels Pancreatic Cancer]]>

<![CDATA[Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.]]>

onclive · 2mo ago↗ source

<![CDATA[Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia]]>

<![CDATA[Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.]]>

onclive · 2mo ago↗ source